Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC22A4 | Q9H015 | 1/20 | 0.52 |
| ▸ | POLB | P06746 | 2/20 | 0.46 |
| ▸ | ALPL | P05186 | 1/20 | 0.46 |
| ▸ | ALPG | P10696 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL188140 | 1.00 | SLC22A4 (0.52) | SLC22A4POLBALPLALPGGAA | |
| Water SCHEMBL7254213 | 0.99 | SLC22A4 (0.51) | SLC22A4POLBALPLALPGGAA | |
| SCHEMBL19571061 | 0.87 | SLC22A4 (0.38) | SLC22A4POLBALPLALPG | |
| SCHEMBL19565055 | 0.87 | SLC22A4 (0.38) | SLC22A4POLBALPLALPG | |
| SCHEMBL13201954 | 0.87 | SLC22A4 (0.38) | SLC22A4POLBALPLALPG | |
| Zinc Ion SCHEMBL7036582 | 0.85 | SLC22A4 (0.37) | SLC22A4POLBALPLALPG | |
| SCHEMBL2218757 | 0.82 | SLC22A4 (0.52) | SLC22A4POLBALPLALPGGAA | |
| SCHEMBL29418359 | 0.82 | SLC22A4 (0.52) | SLC22A4POLBALPLALPGGAA | |
| SCHEMBL29601603 | 0.81 | SLC22A4 (0.51) | SLC22A4POLBALPLALPGGAA | |
| SCHEMBL29705505 | 0.81 | SLC22A4 (0.51) | SLC22A4POLBALPLALPGGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7767826-B2 | Process for the synthesis of L-(+)-ergothioneine | PHARMATECH INTERNATIONAL, INC. (US) | 2010-08-03 | — | — | US | claimed |
| US-20090093642-A1 | PROCESS FOR THE SYNTHESIS OF L-(+)-ERGOTHIONEINE | PHARMATECH INTERNATIONAL, INC. | 2009-04-09 | — | — | US | claimed |
| WO-2009045413-A1 | PROCESS FOR THE SYNTHESIS OF L-(+)-ERGOTHIONEINE | PHARMATECH INTERNATIONAL, INC. (US) | 2009-04-09 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090093642-A1 | PROCESS FOR THE SYNTHESIS OF L-(+)-ERGOTHIONEINE | TTPA, DTYMK, TST | SLC22A4 2504/4885POLB 1148/4885ALPL 3225/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.